Home>Faculty List >Dr. Gelfand
  
 

Joel M. Gelfand, M.D., M.S.C.E.
Medical Director, Clinical Studies Unit
Assistant Professor of Dermatology
Associate Scholar, Center for Clinical Epidemiology and Biostatistics

2 Maloney Building
3600 Spruce Street
Philadelphia, PA 19104
Tel: 215-662-2737
Fax: 215-615-0047

 		 
 

Education
1993        B.S.            Tufts Univerisity
1998        M.D.           Harvard Medical School
2003        MSCE          University of Pennsylvania

Clinical Specialties
Psoriasis
General Dermatology

Research Area of Interest
Clinical Trials, Psoriasis

Research Summary
Dr. Gelfand's research is focused on epidemiology, clinical trials, drug safety, and psoriasis. His epidemiology research focuses on the natural history of psoriasis and the risk of various health outcomes associated with psoriasis such as malignancy, diabetes/metabolic disorders, atherosclerosis/myocardial infarction, and psoriatic arthritis. These studies are examining how the chronic inflammatory nature of psoriasis itself can lead to various health outcomes which share similar immune abnormalities. These studies are important to understanding the impact psoriasis has on a patients health and are informative for planning and interpreting long term safety studies of novel therapies for psoriasis. His clinical trials research focuses on improving efficiency of trials through use of efficient statistical designs and the creation and validation of surrogate endpoints to predict early on in the course of treatment which patients will have a clinical response. He also designs and conducts phase I-IV investigator initiated studies examining novel therapies for disorders such as psoriasis, cutaneous T cell lymphoma, and hidradenitis as well as studies investigating novel applications of imaging devices for skin disease. Dr. Gelfand also serves as an investigator on a number of industry initiated clinical trials of novel therapies for psoriasis and other common skin conditions. Dr. Gelfand’s research has been funded by grants from the National Institute for Arthritis, Musculoskeletal, and Skin Diseases, the Dermatology Foundation, the American Skin Association, and several unrestricted grants from industry.


Selected Research Publications:

  1. Cochrane, DE, Carraway, RE, Feldberg, RS, Boucher, W, and Gelfand, JM. Stimulated Rat Mast Cells Generate Histamine-Releasing Peptide from Albumin. Peptides. 1993;14:117-123.

  2. Arnsten, JH, Gelfand, JM, and Singer, DE. Determinants of Compliance with Anticoagulation: A Case-Control Study. American Journal of Medicine. 1997;103:11-17.

  3. Gelfand, JM, Rudikoff, D, Lebwohl, M, and Klotman, ME. The Effect of Ultraviolet B Phototherapy on HIV-1 RNA Plasma Viral Level: A Prospective Self-Controlled Study. Archives of Dermatology. 1998;134:940-945.

  4. Schwartz, E, Gelfand, JM, Mauch, JC, and Kligman, LH. Modified Polyadenylation Site Selection in Tropoelastin mRNA Prepared from Sun-damaged Human Skin and UV Treated Fibroblasts. Biochemical and Biophysical Research Communications. 1998;246:217-221.

  5. Lehrer, M, Crawford G, Gelfand, JM, Vittorio, C, and Leyden, JJ. The effect of wax epilation prior to hair removal with a long-pulsed alexandrite laser-a pilot study. Dermatologic Surgery. 2003;29: 118-23.

  6. Gelfand, JM, Hoffstad, O, Margolis, DJ. Surrogate Endpoints for the Treatment of Venous Leg Ulcers. Journal of Investigative Dermatology. 2002;119:1420-1425.

  7. Margolis DJ, Gelfand JM, Hoffstad O, Berlin JA. Surrogate endpoints for the treatmentof diabetic neuropathic foot ulcers. Diabetes Care. 2003;26: 1696-1700.

  8. Gelfand, JM, Berlin, J, Van Voorhees, A, and Margolis, DJ. Lymphoma rates are low but increased in patients with psoriasis - results from a population based cohort study in the United Kingdom. Archives of Dermatology. 2003;139: 1425-9.

  9. Gelfand, JM, Feldman, SR, Stern, RS, Thomas, J, Rolstad, T, and Margolis, DJ. Determinants of quality of life in patients with psoriasis: a study from the United States population. Journal of the American Academy of Dermatology. 2004; 51:704-708.

  10. Gelfand, JM, Stern, RS, Nijsten, T, Feldman, SR; Thomas, J, Kist, J; Rolstad, T, and Margolis, DJ. The prevalence of psoriasis in African Americans: Results from a population based study.Journal of the American Academy of Dermatology. 2005; 52:23-6.

  11. Gelfand JM, Crawford, G, Brod, BA, and Szapary, PO. Adverse cutaneous reactions to guggulipid: Results from a randomized, placebo controlled trial.Journal of the American Academy of Dermatology. 2005;52:533-4.

  12. Brown, T, Zirvi, M, Cotsarelis, G, and Gelfand, JM. Vitiligo-like Hypopigmentation Associated with Imiquimod Treatment of Genital Warts. Journal of the American Academy of Dermatology. 2005; 52: 715-716.

  13. Introcaso, CE, Hess, SD, Kamoun, M, Ubriani, R, Gelfand, JM, and Rook, AH. Association of change in clinical status and change in the percentage of the CD4+CD26– lymphocyte population in patients with Sézary syndrome. Journal of the American Academy of Dermatology. 2005;53(3):428-34.

  14. Gupta, G, Gelfand, JM, and Lewis, JD. Increased Risk of Demyelinating Diseases in Patients with Inflammatory Bowel Disease. Gastroenterology. 2005;129(3):819-26.

  15. Gelfand, JM, Gladman, DD, Mease, PJ, Smith, N, Margolis, DJ, Nijsten, T, Stern, RS, Feldman, SR, and Rolstad, T. Epidemiology of Psoriatic Arthritis in the United States Population. Journal of the American Academy of Dermatology. 2005;53:573-7.

  16. Nijsten, T, Whalley, D, Gelfand JM, Margolis, DJ, McKenna, S, and Stern, RS. The psychometric qualities of the Psoriasis Disability Index in the United States Population. Journal of Investigative Dermatology. 2005; 125:665-72.

  17. Gelfand JM, Weinstein, R, Porter, SB, Neimann, AL, Berlin, JA, and Margolis, DJ. Prevalence and treatment of psoriasis in the United Kingdom: A population-based study. Archives of Dermatology. 2005;141:1537-1541.

  18. Gelfand, JM, Shin, DB, Neimann, AL, Wang, X, Margolis, DJ, and Troxel, AB. The risk of lymphoma in patients with psoriasis. Journal of Investigative Dermatology. 2006;126:2194-2201.

  19. Neimann, AL, Hodinka, RL, Joshi, YB, Elkan, M, Van Voorhees, AS, and Gelfand, JM. Epstein-Barr-virus and human herpesvirus type 6 infection in patients with Psoriasis. European Journal of Dermatology. 2006;16:548-52.

  20. Brown, TT, Quain, RD, Troxel, AB, and Gelfand, JM. The epidemiology of sunburn in the U.S. population in 2003. Journal of the American Academy of Dermatology. 2006;55:577-83.

  21. Neimann, AL, Shin, DB, Wang, X, Margolis, DJ, Troxel, AB and Gelfand, JM. Prevalence of cardiovascular risk factors in patients with psoriasis. Journal of the American Academy of Dermatology. 2006; 55:829-35.

  22. Gelfand JM, Neimann, AL, Shin, DB, Wang, X, Margolis, DJ, and Troxel, AB. The risk of myocardial infarction in patients with psoriasis. Journal of the American Medical Association. 2006;296:1735-1741.

  23. Gelfand, JM, Troxel, AB, Lewis, JD, Kurd, SK, Shin, DB, Wang, X, Margolis, DJ, and Strom, BL. The risk of mortality in patients with psoriasis: Results from a population-based study. Archives of Dermatology. 2007;143:1493-1498.

  24. Kurd, SK, Smith, N, VanVoorhees, A, Troxel, AB, Badmaev, V, Seykora, JT, and Gelfand, JM. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: a prospective clinical trial. Journal of the American Academy of Dermatology. In press.


    25.

Selected Reviews and Textbook Chapters:

  1. Clancy, TE, Fiks, AG, Gelfand, JM, et al. A Call for Health Policy Education in the Medical School Curriculum. Journal of the American Medical Association. 1995;274:1084-1085.

  2. Lebwohl, M, Gelfand, JM, and Tan, M.H. Clinically Significant Therapeutic Interactions for the Practicing Dermatologist. Advances in Dermatology. 1999;14:1-26.

  3. Gelfand JM, Mirza N, Kantor J, Yu G, Reale D, Bondi E, Junkins-Hopkins JM. Nodular fasciitis. Archives of Dermatology. 2001;137:719-721

  4. Wei H, Spencer J, Gelfand JM, Phelps R, and Lebwohl M. The Isoflavone Genistein: A New Agent in Dermatology? Cosmetic Dermatology. 2001;14:13-19.

  5. Gelfand, JM, and James WD. Sweet’s Syndrome. In Treatment of Skin Disease. Lebwohl M, Heyman WR, Berth-Jones J, and Coulson I, eds. Mosby. London. 2002

  6. Gelfand, JM, and Rudikoff, D. Evaluation of Pruritus in Patients Infected with the Human Immunodeficiency Virus. Mount Sinai Journal of Medicine. 2002;68:298-308.

  7. Gelfand, JM and Werth, V. Evidence Based Medicine: Treatment of bullous pemphigoid with topical corticosteroids, review of a randomized controlled clinical trial. Archives of Dermatology. 2002;138:1236-7.

  8. Levy, R, Gelfand, JM, and Yan, AC. Epidemiology of Atopic Dermatitis. Advances in Dermatology. 2003;21:109-115.

  9. Gelfand, JM, and Margolis D. Decubitus Ulcers and Venous Ulcers. In Dermatology in General Medicine, Sixth Edition. Freedberg, IM, Eisen AZ, Wolff K, Austen, K Frank, Goldsmith LA, Katz, SI. 2003

  10. Gelfand, JM, Wasik, MA, Vittorio, C et al. Progressive epidermotropic CD8+/CD4-primary cutaneous CD30+ lymphoproliferative disorder in a patient with sarcoidosis. Journal of the Amer Acad of Dermatol.. 2004;51:304-8.

  11. Neimann, AN, Porter, S, and Gelfand JM, Hoffstad O, Berlin JA. Epidemiology of Psoriasis. Expert Review of Dermatology. 2006;1:63-75.

  12. Gelfand, JM, Dattani, H, and Margolis, D. The UK General Practice Research Database. In Pharmacoepidemiology, 4th Edition. Strom, BL ed. Jon Wiley and Sons. West Sussex, England. 2005.

  13. Gelfand, JM. Pharmacovigilance: verifying that drugs remain safe. In Comprehensive Dermatologic Drug Therapy, 2nd Edition. Wolverton, SE ed. Saunders Elsevier. Philadelphia, PA, 2007.

  14. Richardson, SR and Gelfand, JM. Immunobiologicals, cytokines, and growth factors in dermatology. In: Dermatology in General Medicine, 7th edition. Goldsmith, L et al. ed. In press.

  15. Gelfand, JM, Kurd, SK, Neimann, AL, Shin, DB, Margolis, DJ, and Troxel, AB. Psoriasis and Risk of Myocardial Infarction – reply. Journal of the American Medical Association. 2007;297:362-363.

  16. Feldman, SR, Gelfand, JM, Stein Gold, L, Jones, SD. The role of topical therapy for patients with extensive psoriasis. Cutis. 2007;79:18-31.

  17. Kurd, SK, Richardson, SK, and Gelfand, JM. An Update on the Epidemiology and Systemic Treatment of Psoriasis. Expert Review of Clinical Immunology. 2007;3:171-185.

  18. Gelfand, JM. Long-term Treatment for Severe Psoriasis: We’re Halfway There With a Long Way to Go. Archives of Dermatology. 2007; 143:1191-1193.

  19. Pariser, DM, Bagel, J, Gelfand JM, Korman, NJ, Ritchlin, CT, Strober, BE, Van Voorhees, AS, Young, M, Rittenberg, S, Lebwohl, MG, and Horn, EJ. National Psoriasis Foundation clinical consensus on disease severity.Arch Derm. 2007;143:239-242.

  20. Lebwohl, M, Bagel, J, Gelfand, JM, Gladman, D, Gordon, KB, Hsu, S, Kalb, RE, Kimball, AB, Korman, NJ, Kreuger, GG, Mease, P, Morrison, WL, Paller, A, Pariser, DM, Ritchlin, C, Strober, B, Van Voorhees, A, Weinstein, GD, Young, M, and Horn, L. From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis. Journal of the American Academy of Dermatology. 2008;58:94-105.

  21. Kimball, AB, Gladman, D, Gelfand, JM, Gordon, G, Horn, EJ, Korman, NJ, Korver, G, Kreuger, GG, Strober, BE, and Lebwohl, MG. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. Journal of the American Academy of Dermatology in press

    22.

  22. Azfar RS and Gelfand JM. Psoriasis and Metabolic Disease: Epidemiology and Pathophysiology. Current Opinion in Rheumatology 2008;20:416-22

Media Coverage of Dr. Gelfand’s Research:

  1. Psoriasis and the risk of heart attack:

    Print:

    http://www.usatoday.com/news/health/yourhealth/2006-11-12-psoriasis_x.htm

    Wall Street Journal

    Newsday

    http://www.reuters.com/article/healthNews/idUSCOL465991200

    61124

    Dermatology Foundation Publication

    Dermatology World Report

    Skin & Allergy News


    Television:

    http://abclocal.go.com/wpvi/story?sction=healthcheck&id=4647081

    http://cw11.empowereddoctor.com/media_1007.html

    http://cbs3.com/video/?id=31521@kyw.dayport.com

    Internet:

    http://www.healthtalk.com/psoriasis/programs/11_677/index.cfm

  2. Psoriasis and lymphoma

    http://www.sciencedaily.com/releases/2003/11/031118073244.htm

    http://oncologychannel.healthology.com/skin-problems/article1655.htm

    http://www.hinduonnet.com/thehindu/thscrip/print.pl?file=200311
    2000010200.htm&date=2003/11/20/&prd=seta&

    http://nydailynews.healthology.com/skin-problems/article1655.htm

    http://www.oncolink.com/resources/article.cfm?c=3
    &s=8&ss=23&id=10271&month=11&year=2003

  3. Drug Safety

    http://www.dermatologytimes.com/dermatologytimes
    /article/articleDetail.jsp?id=146983

    http://www.highbeam.com/doc/1G1-135648386.html

  4. Sun Protection

    Print:

    The Epidemiology of Sunburn in the United States - Washington Post

    Television:

    http://cbs3.com/video/?id=28778@kyw.dayport.com

    5.
Links of Interest
Privacy Statement | Legal Disclaimer
The University of Pennsylvania Health System. © 2005. The Trustees of University of Pennsylvania